JMP Securities Reiterates Market Perform Rating for Astria Therapeutics (NASDAQ:ATXS)

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “market perform” rating reiterated by equities researchers at JMP Securities in a research note issued to investors on Wednesday,Benzinga reports.

A number of other research analysts have also recently commented on the stock. Evercore ISI reiterated an “outperform” rating and set a $26.00 price target on shares of Astria Therapeutics in a research report on Wednesday, October 1st. Jefferies Financial Group cut shares of Astria Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the company from $30.00 to $13.00 in a research report on Tuesday. Oppenheimer cut shares of Astria Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Astria Therapeutics in a research report on Wednesday, October 8th. Finally, Wedbush set a $13.00 target price on shares of Astria Therapeutics and gave the stock a “neutral” rating in a research note on Wednesday. Three research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $25.00.

Astria Therapeutics Price Performance

Shares of NASDAQ ATXS opened at $12.09 on Wednesday. Astria Therapeutics has a one year low of $3.56 and a one year high of $12.52. The firm’s 50 day simple moving average is $7.44 and its two-hundred day simple moving average is $6.03. The stock has a market capitalization of $682.36 million, a P/E ratio of -6.01 and a beta of 0.43.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.04. As a group, equities analysts expect that Astria Therapeutics will post -1.65 earnings per share for the current fiscal year.

Institutional Trading of Astria Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC boosted its holdings in Astria Therapeutics by 185.8% in the second quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 3,557 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Astria Therapeutics by 1,127.4% in the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 7,971 shares in the last quarter. Brooklyn Investment Group boosted its holdings in Astria Therapeutics by 1,079.6% in the first quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 7,957 shares in the last quarter. Corton Capital Inc. bought a new stake in Astria Therapeutics in the first quarter valued at $72,000. Finally, AlphaQuest LLC boosted its holdings in Astria Therapeutics by 100.9% in the first quarter. AlphaQuest LLC now owns 14,216 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 7,139 shares in the last quarter. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.